Hummel S, Lehtonen L
Fachkrankenhaus für Lungenheikunde und Thoraxchirurgie, Berlin, Germany.
Lancet. 1992;340(8834-8835):1483-7. doi: 10.1016/0140-6736(92)92750-a.
It is not clear whether high doses of inhaled steroids have a greater sparing effect than low doses on the requirement for systemic steroids. In a randomised, double-blind, multicentre study, we compared the effects of high-dose (1500 micrograms/day) and low-dose (300 micrograms/day) inhaled beclomethasone dipropionate (BDP) in patients with severe asthma requiring a daily oral prednisolone dose of 10-40 mg. During a 3-month run-in period, we tried to achieve optimum asthma control by means of oral steroid and inhaled BDP 300 micrograms/day. The patients were then allocated to high-dose (n = 71) or low-dose (n = 72) treatment by an independent observer who took into account various prognostic factors. BDP was administered by means of an aerosol inhaler with a spacer device. The dose of systemic steroid was reduced as much as possible during the 6-month study period while keeping the peak expiratory flow (PEF) constant and asthma clinically stable. There was no difference between the low-dose and high-dose treatment groups in the mean reduction in oral prednisolone dose achieved by the end of the study (5.2[ SD 7.9] vs 5.0 [9.4] mg/day). The maximum response to inhaled steroid was seen, however, only after several months' therapy in both groups. There were no differences between the groups in use of on-demand beta-agonist inhalations or in asthma symptoms, and PEF values were constant throughout the study. Both doses of BDP were well tolerated. High doses of inhaled steroid offer no further benefit over low doses in the maintenance treatment of severe steroid-dependent asthma when the inhaled steroid is administered with a spacer device.
高剂量吸入性类固醇在减少全身性类固醇需求方面是否比低剂量具有更大的节省效应尚不清楚。在一项随机、双盲、多中心研究中,我们比较了高剂量(1500微克/天)和低剂量(300微克/天)吸入丙酸倍氯米松(BDP)对每日口服泼尼松龙剂量为10 - 40毫克的重度哮喘患者的影响。在为期3个月的导入期内,我们试图通过口服类固醇和每日300微克吸入BDP来实现最佳哮喘控制。然后,由一名考虑了各种预后因素的独立观察者将患者分配至高剂量组(n = 71)或低剂量组(n = 72)进行治疗。BDP通过带有间隔装置的气雾剂吸入器给药。在为期6个月的研究期间,尽可能减少全身性类固醇的剂量,同时保持呼气峰值流速(PEF)恒定且哮喘临床症状稳定。在研究结束时,低剂量和高剂量治疗组在口服泼尼松龙剂量的平均减少量方面没有差异(分别为5.2[标准差7.9]和5.0[9.4]毫克/天)。然而,两组均在治疗数月后才出现对吸入性类固醇的最大反应。两组在按需使用β-激动剂吸入或哮喘症状方面没有差异,并且在整个研究过程中PEF值保持恒定。两种剂量的BDP耐受性都很好。当使用间隔装置吸入类固醇时,高剂量吸入性类固醇在重度类固醇依赖型哮喘的维持治疗中并不比低剂量提供更多益处。